As a new-type foreign trade service provider driven by both technology transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply raw materials from multiple well-known original manufacturers of Ticagrelor Intermediate.
Unlike single-brand factories that only promote their own products, HiSiaddi, as an R&D-oriented foreign trade service provider, objectively analyzes multiple top market-share brands in China and globally and shares their major technological progress and breakthroughs, enabling buyers to access authentic, effective and up-to-date market intelligence.
If you require more comprehensive and valuable market information on Ticagrelor Intermediate, please contact HiSiaddi’s customer service team.
Breakthrough Highlights: Microchannel continuous flow nitration new process industrialized for NPPD core intermediate (Ticagrelor pyrimidine mother nucleus). Industrial yield rises from 79.8% under traditional batch nitration to 92.4%, an increase of 12.6%; reaction residence time compressed from 720 minutes to 285 seconds; single-batch production cycle cut from 3 days to 8 hours. Temperature deviation for strong exothermic nitration reactions narrowed from ±6°C to ±0.8°C, eliminating localized overheating that generates genotoxic nitro impurities. Supporting Improvements: Full-line PAT online process analysis systems deployed to monitor intermediate purity in real time; batch-to-batch purity fluctuation reduced from ±0.35% to ±0.07%.
1. Indicator Breakthrough by Xinhua Pharmaceutical for Chiral Intermediates For (1R,2S)-difluorophenyl cyclopropanecarboxylic acid methyl ester chiral intermediate, a recyclable cobalt-based chiral ligand catalytic resolution new technology raises chiral ee value from 99.50% to 99.93%; per kilogram consumption of chiral catalysts drops by 78%; single impurity reduced from 220ppm to ≤12ppm, meeting the highest internal control standards of USP and EP pharmacopoeias. A 500-ton intelligent production line passed FDA on-site inspections and commenced mass exports to European and American generic pharmaceutical manufacturers in 2026.
2. Industrialized Green Enzymatic Route New Patent by Minova Pharmaceutical (April 2026 Launch) For TCAB series side-chain intermediates, biological enzymatic reduction replaces chemical metal reduction, eliminating chromium and nickel heavy metal reducing agents. Total intermediate impurities drop from 0.28% to 0.09%; solvent consumption cut by 37%; highly toxic solvents such as toluene replaced with isopropyl acetate; finished products fully REACH-compliant without restricted residues.
Breakthrough Highlights: Traditional phosphorus oxychloride acylation reagents eliminated for Ticagrelor cyclization intermediates, replaced with modified molecular sieve solid acid catalysis. Production wastewater COD reduced from 12800mg/L to 4860mg/L (62% reduction); hazardous solid waste output cut by 51%; internal control heavy metal residues of finished products <0.5ppm; raw material unit consumption down 14.7%, with an 8.2% drop in ex-factory intermediate costs.
Breakthrough Highlights: Genetically engineered bacillus enzyme catalytic new process completed industrialization in early 2026 for Ticagrelor key cyclopropane intermediates. The traditional 5-step chemical synthesis is condensed into single-step enzymatic synthesis with diastereoselectivity dr＞99% and chiral ee=98.2%; total yield lifted from 61% to 79.1%. High-risk multi-step diazotization reactions are avoided; in-house intermediate production costs for original research dropped by 15.3%, with customized intermediate export business newly opened simultaneously.
Breakthrough Highlights: Resin-NO₂ immobilized resin catalysts replace liquid sodium nitrite diazotization reagents for triazole ring construction intermediates. Diazotization by-products reduced by 67%; overall intermediate purity elevated from 99.21% to 99.79%. Resin catalysts can be recovered and reused for 18 cycles, resolving the pain point of excessive hydrolysis impurities during India’s rainy seasons. Mass supply to Southeast Asian generic pharmaceutical manufacturers expanded significantly in 2026.
Breakthrough Highlights: Modular continuous production lines for full series of Ticagrelor intermediates launched. The proportion of effective single β crystal form of intermediates raised from 97.2% to 99.1% without invalid mixed crystals; batch dissolution fluctuation of identical specifications narrowed from ±2.1% to ±0.4%. Line switching time between different intermediate specifications shortened from 72 hours to 12 hours, enabling rapid response to small-batch customized demand from buyers.
Breakthrough Highlights: Closed-loop by-product recovery processes deployed. Diol derivative by-products from intermediate synthesis are cyclically converted back to starting epoxy raw materials, boosting raw material atom utilization rate by 21%. Volatile solvents undergo full condensation recovery with solvent reuse rate rising from 62% to 93%; FOB quotation of all intermediates cut by 6.7% year-on-year. DMF filing documents for all intermediates updated simultaneously to comply with new FDA impurity control regulations for the US market.
1. Cost Benefits for Procurement Reduced raw material unit consumption and solvent recovery by leading domestic intermediates drive a year-on-year 7%~11% decline in spot purchase prices. Original research overseas brands offer 5%~8% expanded negotiation space for long-term framework orders relying on by-product recycling, enabling large-batch price locking to avoid raw material price hikes.
2. Supply Chain Delivery Benefits Continuous flow technology lifts production capacity flexibility by over 30%; standard lead times shortened from 28 days to 12–16 days, with small-batch emergency replenishment available within 7 days. All leading manufacturers hold CEP and FDA-DMF qualifications for full intermediate series, eliminating additional supplier audit requirements for buyers and cutting compliance access cycles by 60%.
3. Risk Control Benefits Impurities are comprehensively lowered below internal control upper limits set by pharmacopoeias, drastically reducing re-inspection, rework and return losses from incoming materials; incoming material disqualification rates dropped from the historical 1.8% to below 0.2%.
1. Production Cost Benefits Optimized upstream intermediate impurities reduce consumption of activated carbon and extraction solvents in downstream API refining sections by 23%; API refining yield lifted by 3%~5%, cutting formulation production costs by 4%~6%.
2. Registration Filing Benefits Genotoxic impurities and heavy metals in intermediates are far below EP/USP limits, cutting impurity spectrum research workload by 40% for generic drug consistency evaluation and ANDA filings in Europe and America, shortening drug approval timelines.
3. Production Line Stability Benefits Stable intermediate crystal forms and controllable dissolution reduce process fluctuations in tablet compression and coating procedures of finished formulations, significantly improving batch consistency of tablet disintegration time and dissolution rate and cutting formulation scrapping losses.
Upgraded quality of upstream intermediates lowers impurity levels in finished Ticagrelor APIs, reducing impurity exposure risks for oral tablets and further optimizing incidence rates of clinical adverse reactions such as bleeding and liver-kidney impairment. Products meet high-quality generic drug procurement standards of European and American medical insurance centralized bidding, supporting price reductions of finished drugs to benefit patients.
For more comprehensive and valuable market information on Ticagrelor Intermediate, please contact HiSiaddi’s customer service team.
+86-13120989737 
info@hisiaddi.com 
English
